Special Issue

Innovations in Antibacterial Agents: Combating Resistance, Improving Efficacy and Exploring New Mechanisms

Message from the Guest Editors

The inappropriate use of antibacterial agents has promoted the emergence of resistant strains of bacteria and poses a significant threat to public health. The pervasive problem of antimicrobial resistance is exacerbating healthcare crises worldwide, leading to increased mortality rates and rising healthcare costs. This Special Issue aims to present a broad spectrum of research in the field of medicinal chemistry of antibacterial compounds and we welcome manuscripts that address both traditional and computational drug design strategies, from target identification to the application of machine learning and the screening of diverse chemical libraries in the discovery processes. In terms of publication priorities, modern methods, including virulence factor inhibitors, nanoparticles, antimicrobial peptides, phage therapy, and antisense oligonucleotides, are at the forefront. Papers dealing with the design and synthesis of new classes of antibacterial agents that introduce novel mechanisms of action, as well as studies focusing on the chemical synthesis and optimization of existing antibacterial agents, whether semi-synthetic or fully synthetic, are also welcome.

Guest Editors

Dr. Rok Frlan

The Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia

Dr. Martina Hrast

Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia

Deadline for manuscript submissions

20 February 2026



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/200910

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

